Screener
Kyverna Therapeutics, Inc. KYTX Free cash flow
Free cash flow at other companies
Other financials
Where this comes from
Calculated from Kyverna Therapeutics, Inc.’s reported figures.
The source filing: Kyverna Therapeutics, Inc.’s 10-K, filed March 26, 2026. Open the filing →
- Filed
- Mar 26, 2026, 4:11 PM EDT
- Fiscal year
- FY2025
- Accession
- 0001193125-26-126242
FAQ
- What is Kyverna Therapeutics, Inc.'s free cash flow?
- Kyverna Therapeutics, Inc. (KYTX) reported free cash flow of -$33.53M in Q4 2025.
- How has Kyverna Therapeutics, Inc.'s free cash flow changed year-over-year?
- Kyverna Therapeutics, Inc.'s free cash flow increased by 10.8% year-over-year, from -$37.59M to -$33.53M.
- What is the long-term trend for Kyverna Therapeutics, Inc.'s free cash flow?
- Over 2 years (2023 to 2025), Kyverna Therapeutics, Inc.'s free cash flow has grown at a 70.3% compound annual growth rate (CAGR), from -$53.03M to -$153.72M.
- What does free cash flow mean?
- Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.
Ask your AI about Kyverna Therapeutics, Inc.'s free cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude